top of page

Pharma - Case Studies

At C&C Group we partner with pharmaceutical organisations to deliver secure, resilient and fully compliant technology environments that underpin critical operations. Our case studies demonstrate how we support healthcare and pharma clients by hosting and managing central systems, strengthening regulatory compliance frameworks, and enabling data-driven transformation across complex environments.

Case Study – Disclosure UK (ABPI)

What It Is

The Disclosure UK search portal and underlying systems are developed and maintained by C&C Group—on behalf of the ABPI. This includes both the public-facing searchable database and the private portal for pre-publication review and data correction.

​

Since 2019, C&C Group has been the Association of the British Pharmaceutical Industry’s (ABPI) trusted technology and managed services partner for Disclosure UK, a national transparency platform forming part of a Europe-wide initiative to improve openness between the pharmaceutical industry and healthcare professionals (HCPs) and healthcare organisations (HCOs).

​

The contract has been repeatedly extended through open procurement, reflecting confidence in C&C Group’s performance, reliability, and value.

​

C&C Group integrates data ingestion, database management, search and authenticated review workflows. The solution provides a clear data lifecycle from company submission to public publication, supported by compliance controls, privacy safeguards and methodological transparency. C&C Group designed, built, and continues to operate the platform using a scalable, end-to-end managed service model, combining bespoke system development with ongoing operational support, continuous improvement, and deep regulatory expertise.

​

​

Scalable by Design

The Disclosure UK platform has been engineered to scale year on year in both data volume and user demand. The platform utilises modern scalable components to enable horizontal, vertical and autoscaling to respond to increases in demand, platform reviews, and technology improvements.

​

The platform is designed with scale in mind, always giving headroom to scale up/down (vertical scaling). This is achieved by increasing base processing power, memory, or other components within existing resources. This activity lends itself better to actions resulting from platform reviews, pro-active monitoring, KPIs, etc.

​

Not only does scaling reside in the Infrastructure level but also the application itself. Software is developed to take advanced of scaling Infrastructure where possible by utilising reduced server-side session state, reducing client affinity, distributed cache, background tasks, etc.

​

Each annual disclosure cycle creates a significant operational challenge, with all pharmaceutical companies submitting data to the same deadline. We process and match hundreds of thousands of records in a compressed timeframe, using advanced data-matching algorithms to prevent duplicate HCP and HCO records caused by inconsistent data entry.

​

The platform currently supports:

​

  • 150+ pharmaceutical companies submitting disclosure data

  • 48,000+ active users across industry, healthcare, and the public

  • Hundreds of thousands of records processed and matched annually, annual value in 2023 was £692.5m increasing to £813.3million in 2024

  • 30,000+ automated emails and letters generated per disclosure cycle

​

This scale is delivered consistently without performance degradation, demonstrating a repeatable and resilient operating model.

End-to-End Value and Benefits

C&C Group provides full lifecycle services including system design, development, operation, and support. This is complemented by Business Process Outsourcing (BPO) services such as query handling, telephone support, manual data matching, and bespoke reporting. This approach significantly reduces operational burden for ABPI while maintaining high data accuracy, auditability, and regulatory compliance.

​

The platform is built on robust, industry-standard technologies (.NET, SQL Server) and undergoes regular technical refreshes to ensure security, performance, and long-term sustainability. Continuous enhancement is embedded into the service, enabling Disclosure UK to evolve without disruption.

Strategic Impact and Future Readiness

Beyond operational delivery, C&C Group acts as a strategic partner, providing trusted guidance on both technical and process improvements. Ongoing innovation includes AI-driven proof-of-concept initiatives to further improve data-matching accuracy and efficiency, strengthening scalability as data volumes continue to grow.

​

The solution is also designed for functional expansion, with discussions underway to introduce additional disclosure demographics, reinforcing long-term confidence and adaptability.

Outcomes for ABPI

Disclosure UK is strategically important to ethical transparency and stakeholder trust within the pharmaceutical sector.

​

Through C&C Group’s delivery, ABPI has achieved:

​

  • Reduced administrative burden for both ABPI and pharmaceutical companies

  • High confidence in data accuracy and completeness

  • Greater transparency and public trust

  • Assurance that the platform remains robust, scalable, auditable, and compliant

​

C&C Group has delivered a highly scalable, future-ready platform that combines technology excellence, operational resilience, and deep domain expertise—positioning Disclosure UK to meet growing demand without compromising performance, accuracy, or trust.

bottom of page